Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended December 31, 1998, for Aastrom Biosciences, Inc. (Note: The input metadata referenced "Vericel Corp," but the filing text explicitly identifies the registrant as Aastrom Biosciences, Inc.). The Company is a development-stage entity focused on the research and product development of processes for the ex vivo production of human cells for cell and ex vivo gene therapy. Its lead product candidate is the AastromReplicell Cell Production System.
Key Financial Metrics
| Metric | Six Months Ended Dec 31, 1998 | Six Months Ended Dec 31, 1997 | Three Months Ended Dec 31, 1998 |
|---|---|---|---|
| Total Revenues | $370,000 | $65,000 | $207,000 |
| Total Costs & Expenses | $7,605,000 | $8,527,000 | $3,861,000 |
| Net Loss | $(5,638,000) | $(8,033,000) | $(2,276,000) |
| Net Loss Per Share (Basic/Diluted) | $(0.42) | $(0.87) | $(0.16) |
| Cash & Cash Equivalents (End of Period) | $9,852,000 | $1,270,000 | $9,852,000 |
| Short-Term Investments | $1,000,000 | $9,134,000 | $1,000,000 |
| Total Current Liabilities | $1,804,000 | $1,528,000 | $1,804,000 |
| Accumulated Deficit (Inception to Date) | $(64,818,000) | $(58,897,000) | $(64,818,000) |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased significantly to $370,000 for the six months ended Dec 31, 1998, compared to $65,000 in the prior year period, driven by increased research grant funding.
- Expense Reduction: Total costs and expenses decreased by approximately 11% year-over-year for the six-month period ($7.6M vs $8.5M). This reduction was primarily due to a 15% workforce reduction in November 1998 affecting 19 staff positions and a decrease in non-cash charges compared to 1997.
- One-Time Income: The net loss for the period includes a one-time gain of $1,237,000 recorded as "Other Income" resulting from the termination of a distribution agreement with Cobe BCT, Inc.
- Liquidity Shift: While cash and cash equivalents increased to $9.85 million, short-term investments decreased from $9.13 million to $1.0 million, reflecting a shift in asset allocation and cash usage for operations.
- Capital Structure: In December 1998, all 2.2 million shares of 5.5% Convertible Preferred Stock were converted into common stock. Additionally, 1,000 shares of Series I Preferred Stock were converted into common stock.
Guidance, Outlook, and Risks
- Outlook: Management does not expect to generate positive cash flows from operations for at least the next several years. The Company anticipates its current cash resources will fund operations through mid-1999.
- Future Funding: The Company expects to seek additional funding through collaborative arrangements, grants, or public/private financing. There is no assurance such funding will be available on acceptable terms.
- Product Development: The Company is conducting clinical trials for the AastromReplicell System. Initial U.S. pivotal clinical trials began in December 1998. European market introduction is underway following CE Mark approval.
- Key Risks:
- Regulatory Approval: No assurance that FDA or European regulatory approvals will be obtained.
- Commercialization: Uncertainty regarding market acceptance and the ability to secure new distribution partners following the Cobe termination.
- Supply Chain: Dependence on third parties for manufacturing key components and cytokines.
- Year 2000 Compliance: Potential risks related to supplier systems not being Year 2000 compliant.
Investor Verification Checklist
- Verify the status and results of the U.S. pivotal clinical trials initiated in December 1998.
- Confirm the timeline and terms of any new distribution or marketing agreements to replace the terminated Cobe agreement.
- Monitor cash burn rate to validate the management estimate of funding sufficiency through mid-1999.
- Review the progress of European CE Mark compliance and market introduction activities.
- Assess the impact of the November 1998 workforce reduction on ongoing R&D timelines.